289 related articles for article (PubMed ID: 22001585)
1. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study.
Pickham D; Helfenbein E; Shinn JA; Chan G; Funk M; Weinacker A; Liu JN; Drew BJ
Crit Care Med; 2012 Feb; 40(2):394-9. PubMed ID: 22001585
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and determinants of QT interval prolongation in medical inpatients.
Pasquier M; Pantet O; Hugli O; Pruvot E; Buclin T; Waeber G; Aujesky D
Intern Med J; 2012 Aug; 42(8):933-40. PubMed ID: 21299787
[TBL] [Abstract][Full Text] [Related]
4. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients.
Tisdale JE; Jaynes HA; Kingery JR; Mourad NA; Trujillo TN; Overholser BR; Kovacs RJ
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):479-87. PubMed ID: 23716032
[TBL] [Abstract][Full Text] [Related]
6. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
[TBL] [Abstract][Full Text] [Related]
7. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
[TBL] [Abstract][Full Text] [Related]
8. Female gender as independent risk factor of torsades de pointes during acquired atrioventricular block.
Chorin E; Hochstadt A; Viskin S; Rozovski U; Havakuk O; Baranchuk A; Enriquez A; Strasberg B; Guevara-Valdivia ME; Márquez MF; González-Pacheco H; Hasdemir C; Rosso R
Heart Rhythm; 2017 Jan; 14(1):90-95. PubMed ID: 27650425
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients.
Tisdale JE; Jaynes HA; Kingery JR; Overholser BR; Mourad NA; Trujillo TN; Kovacs RJ
Circ Cardiovasc Qual Outcomes; 2014 May; 7(3):381-90. PubMed ID: 24803473
[TBL] [Abstract][Full Text] [Related]
10. Predictive Validity of a QT
Su K; McGloin R; Gellatly RM
Pharmacotherapy; 2020 Jun; 40(6):492-499. PubMed ID: 32259316
[TBL] [Abstract][Full Text] [Related]
11. The Incidence of QT Prolongation and Torsades des Pointes in Patients Receiving Droperidol in an Urban Emergency Department.
Cole JB; Lee SC; Martel ML; Smith SW; Biros MH; Miner JR
West J Emerg Med; 2020 Jul; 21(4):728-736. PubMed ID: 32726229
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Medication Associated with QTc Prolongation Used Among Critically Ill Patients.
Al-Azayzih A; Al-Qerem W; Al-Azzam S; Muflih S; Al-Husein BA; Kharaba Z; Kanaan RJ; Rahhal D
Vasc Health Risk Manag; 2024; 20():27-37. PubMed ID: 38318252
[TBL] [Abstract][Full Text] [Related]
13. Hyperglycemia is associated with corrected QT prolongation and mortality in acutely ill patients.
Pickham D; Flowers E; Drew BJ
J Cardiovasc Nurs; 2014; 29(3):264-70. PubMed ID: 23364575
[TBL] [Abstract][Full Text] [Related]
14. Corrected QT Interval Prolongation in Hospitalized Pediatric Patients Receiving Methadone.
Schwinghammer AJ; Wilson MD; Hall BA
Pediatr Crit Care Med; 2018 Aug; 19(8):e403-e408. PubMed ID: 29894447
[TBL] [Abstract][Full Text] [Related]
15. Implications of continuous QT monitoring in the intensive care setting.
Bunch TJ; Mahapatra S
Crit Care Med; 2012 Feb; 40(2):658-9. PubMed ID: 22249035
[No Abstract] [Full Text] [Related]
16. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
18. Preventing torsades de pointes by careful cardiac monitoring in hospital settings.
Sommargren CE; Drew BJ
AACN Adv Crit Care; 2007; 18(3):285-93. PubMed ID: 18019519
[TBL] [Abstract][Full Text] [Related]
19. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients.
Freeman BD; Dixon DJ; Coopersmith CM; Zehnbauer BA; Buchman TG
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):971-81. PubMed ID: 18693297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
